Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: Effect on chronic graft-vs.-host disease and long-term survival  by Ross, Maureen et al.
INTRODUCTION 
Successful allogeneic bone marrow transplantation
(BMT) depends on the interaction of several factors affect-
ing graft failure, infection, graft-vs.-host disease (GVHD),
and disease relapse. GVHD is a particularly important pre-
dictor of outcome in BMT; for patients alive at day 100,
chronic GVHD is a major determinant of survival and qual-
ity of life [1,2].
After undergoing genotype-matched sibling donor
B M T, 40–50% of patients can be expected to develop
c h ronic GVHD [1,2]. The relationship between acute and
c h ronic GVHD is incompletely understood, but acute
GVHD remains the predominant risk factor for chro n i c
GVHD [3,4]. In patients not developing acute GVHD, the
i m p o rtance of increasing age and alloimmunization of
female donors for male recipients is recognized. A variety of
immunosuppressive agents, alone and in combination, have
been used as prophylaxis for acute GVHD. Prospective ran-
domized trials have demonstrated that combination therapy
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ABSTRACT
Graft-vs.-host disease (GVHD) is a major predictor of outcome following allogeneic bone marrow transplantation
(BMT). For patients alive at day 100 after BMT, the presence or absence of chronic GVHD is one of the most
i m p o rtant determinants of survival and quality of life. We wished to determine the effects on chronic GVHD of two
regimens used for the prophylaxis of acute GVHD: cyclosporine, methotrexate, and prednisone (CSA/MTX/PSE)
and cyclosporine and prednisone (CSA/PSE). One hundred forty-nine evaluable patients were entered into the
acute GVHD study. As of 31 March 1997, 63 months after the last patient underwent BMT, the median surv i v a l
time was 4.5 years (range 0.09–9.9). The incidence of chronic GVHD was independent of the prophylactic re g i m e n
(55 vs. 54%), and extensive chronic GVHD occurred in 25 and 24% of patients receiving CSA/MTX/PSE and
CSA/PSE, re s p e c t i v e l y. Of note, the median Karnofsky perf o rmance status of both groups was 100% (range
70–100%), re flecting the low incidence of extensive chronic GVHD. Survival rates free of chronic GVHD were 52
vs. 42% (p 5 0.29) for patients receiving CSA/MTX/PSE vs. CSA/PSE. The incidence of relapse was also similar in
both groups of patients. These data suggest that the combinations of CSA/MTX/PSE and CSA/PSE result in com-
parable chronic GVHD–free survival without an increase in leukemic re l a p s e .
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is superior to single-agent therapy in the prevention of acute
GVHD. Cyclosporine plus methotrexate is superior to
either agent alone, and cyclosporine plus prednisone is
superior to cyclosporine alone or methotrexate plus pre d-
nisone [5–9]. Despite demonstrable reduction in the inci-
dence of acute GVHD by combination immunosuppressive
therapy, most trials have shown relatively constant rates of
c h ronic GVHD. In one study, methotrexate and cyclo-
sporine significantly reduced the incidence of grade II–IV
acute GVHD compared with cyclosporine alone (33 vs.
54%), but the incidence of chronic GVHD was not differ-
ent with combined vs. single-agent therapy [7].
We have previously re p o rted results of a randomized
p rospective trial demonstrating the superiority of cyclo-
s p o r i n e / m e t h o t re x a t e / p rednisone (CSA/MTX/PSE) over
c y c l o s p o r i n e / p rednisone (CSA/PSE) in reducing the inci-
dence of grade II–IV acute GVHD in patients undergoing
HLA-matched sibling allogeneic BMT [10]. In the present
re p o rt, we analyzed the effect of these two acute GVHD
p rophylaxis regimens on chronic GVHD and long-term
s u rvival. Patients in this study were good-risk patients
t reated with a uniform pre p a r a t o ry regimen (fractionated
total-body irradiation [FTBI] and etoposide) who were ran-
domized to receive either CSA/MTX/PSE or CSA/PSE for
prophylaxis against acute GVHD.
PATIENTS AND METHODS
Patient characteristics
Between December 1986 and December 1991, 149
patients were evaluated in a randomized GVHD prophylaxis
trial. The patients had acute leukemia in first remission or
chronic myelogenous leukemia (CML) in first chronic phase
and were undergoing an MHC-identical sibling donor bone
m a rrow transplantation at City of Hope National Medical
Center or Stanford University Medical Center. Wr i t t e n
i n f o rmed consent was obtained. Patients were randomized
to receive either a thre e - d rug (CSA/MTX/PSE) or two-
d rug (CSA/PSE) regimen as GVHD prophylaxis [10].
Before randomization, patients were stratified according to
age and diagnosis. Demographic data and disease character-
istics are shown in Table 1. Sixty-seven patients with CML
in first chronic phase, 50 patients with acute myeloid
leukemia (AML) in first complete remission, and 32 patients
with acute lymphoblastic leukemia (ALL) in first complete
remission are included. Disease-specific outcome for the
patients with CML in the present study has been previously
re p o rted [11], as has outcome for patients with acute
leukemia [12]. The date of analysis for this study was 31
M a rch 1997, 63 months after the last patient underw e n t
B M T. Median survival time for all patients was 4.5 years
(range 0.09–9.9). 
P re p a r a t o r y re g i m e n
All patients received FTBI in combination with high-
dose etoposide (VP-16). TBI consisted of 1320 cGy deliv-
ered in 11 equal fractions on days –7 to –4, with lung shield-
ing and compensatory boost treatment to the chest wall and
ribs with electrons. VP-16 (60 mg/kg actual body weight)
was infused over 4 hours on day –3, as previously described
[11]. All patients were transplanted with genotypically iden-
tical sibling bone marro w. Bone marrow was harv e s t e d
under anesthesia with a collection goal of 23108 total nucle-
ated cells/kg recipient weight. Bone marrow infusion
occurred on day 0. Bone marrow was unmanipulated except
for removal of red blood cells or plasma in the case of a
major ABO mismatch.
GVHD pr o p hy l a x i s
All patients were voluntarily included in a randomized
prospective trial comparing the two-drug regimen of cyclo-
sporine and methylprednisolone with a three-drug regimen
consisting of the same two-drug schedule plus three doses of
methotrexate on days 1, 3, and 6. Initial results of this ran-
domized study were previously reported [10].
Seventy-four patients received the two-drug pro g r a m
and 75 patients received the thre e - d rug program. One
patient receiving the two-drug regimen was not evaluable
for acute GVHD because of death on day 19. The prophy-
lactic regimens were administered as follows. CSA (5 mg/kg)
by continuous infusion was initiated on day –2. The dose
was subsequently adjusted as indicated by serum cyclo-
sporine concentrations measured at least twice a week by
immunoassay (TDx; Abbot Laboratory, Abbot Park, IL).
Intravenous cyclosporine was continued until day 35, at
which time patients were eligible for oral CSA, 5 mg/kg
twice a day. In the absence of acute GVHD, CSA was
t a p e red off by day 180. For patients on the thre e - d ru g
re g imen, methotrexate was administered intravenously at
15 m g / m2 on day 1 and 10 mg/m2 on days 3 and 6. The
MTX dose was adjusted for significant renal or hepatic dys-
function or extensive mucositis. PSE was begun on day 7 at
0.25 mg/kg intravenously b.i.d. and increased to 0.5 mg/kg
intravenously b.i.d. on day 15. On day 29, oral prednisone
Table 1. Patient characteristics/outcome
CSA/PSE/MTX CSA/PSE p
n 75 74
Disease, n (%)
ALL 16 (21) 16 (22) 0.99*
AML 25 (33) 25 (34)
CML 34 (45) 33 (45)
Age at time of BMT (years)
Median 27 31 0.31†
Range (2–48) (1–50)
Day 100 platelet count
Median 66 (n 551) 108 (n 548) 0.07†
Range 13–324 13–247
Karnofsky performance status
as of January 1999 
Median 100% 100% 0.73†
Range 70–100 80–100
Overall survival at 5 years 66 6 11 56 6 11 0.28†
Disease-free survival
at 5 years 62 6 11 57 6 11 0.42†
Chronic GVHD–free survival
at 5 years 52 6 11 42 6 11 0.29†
p values were determined by *Fisher’s exact test and †Wilcoxon’s rank sum test.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML,
chronic myelogenous leukemia; CSA, cyclosporine; GVHD, graft-vs.-host dis-
ease; MTX, methotrexate; PSE, prednisone.
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was substituted, and the dose was slowly tapered from day
29 to day 180. The assessment and treatment of acute
GVHD has been reported [10]. 
Grading of chronic GVHD
The diagnosis of chronic GVHD was made by standard
clinical and histologic criteria, as previously described [2].
The diagnosis was confirmed histologically by biopsy of skin
and other affected tissues when clinically permissible. Nei-
ther biopsy of oral mucosal lesions nor Schirm e r ’s test to
evaluate ocular involvement was routinely perf o rm e d .
Chronic GVHD was graded as limited or extensive accord-
ing to previous convention [13].
S u p p o rt i v e care
All patients were housed in private rooms with a high-
e fficiency particle air filtration system. Antimicrobial pro-
phylaxis consisted of gut contamination with oral neomycin
and vancomycin, oral trimethoprim-sulfamethoxazole, and a
low bacterial diet beginning on day –8. On day 1, all patients
received low-dose amphotericin (0.15 mg/kg). Gamma glob-
ulin (500 mg/kg) was administered weekly from day –7 to
day 100. Blood products were uniformly irradiated with 2500
c G y, and patient/donor pairs who were seronegative for
CMV received seronegative blood products. CMV- s e ro p o s i-
tive patients or recipients of CMV-positive grafts underw e n t
b ronchoalveolar lavage on day 35, with institution of pro-
phylactic ganciclovir if positive for CMV.
Statistical anal y s i s
The major statistical endpoints of this analysis were
incidence of chronic GVHD, overall survival, disease-fre e
s u rvival, and chronic GVHD–free survival. Continued
chronic GVHD–free survival is defined as survival without
evidence of chronic GVHD and without immunosuppre s-
sive agents. Survival distributions were estimated using the
method of Kaplan and Meier and compared using the log-
rank statistic. Patient characteristics and outcome in the two
t reatment groups were compared by Wi l c o x o n ’s rank sum
test for continuous data and by Pearson’s x2 test or Fisher’s
exact test for frequency data. All tests used an alpha level of
0.05 and a two-sided alternative hypothesis. 
RESULTS
E n t r y data
Characteristics of the patients treated with the two
GVHD prophylactic regimens are summarized in Table 1.
CSA/MTX/PSE was administered to 34 patients with
CML, 25 patients with AML, and 16 patients with ALL.
Patients receiving CSA/PSE included 33 patients with
CML, 25 patients with AML, and 16 patients with ALL.
The groups were well matched for patient age (median 27
vs. 31 years, with comparable ranges). No diff e rence in
d o n o r- recipient pair matching for sex or parity existed
between the two groups.
Acute GVHD
Grade II–IV acute GVHD occurred in 9% of patients
receiving CSA/MTX/PSE and 23% of patients re c e i v i n g
CSA/PSE. Of patients on CSA/MTX/PSE, 65% did not
develop acute GVHD vs. 62% of patients on CSA/PSE.
Grade IV acute GVHD was observed in one patient on the
triple-drug regimen and two patients on CSA/PSE. For sta-
tistical comparison, patients were subdivided into those
experiencing grade 0–I GVHD and grade II–IV acute
GVHD. The incidence of acute GVHD was significantly
less for the group receiving methotrexate (p = 0.02), as pre-
viously reported [10].
C h r onic GVHD
The incidence of chronic GVHD was independent of
the acute GVHD prophylactic regimen (55 vs. 54%) (Table
1). Limited chronic GVHD occurred in 25 and 24% of
patients receiving CSA/MTX/PSE and CSA/PSE, re s p e c-
t i v e l y. Extensive chronic GVHD was noted in 21–22% of
patients receiving either prophylactic regimen. Karn o f s k y
scores of the two groups (as of January 1999) are also sum-
marized and did not differ between the two arms. The
median Karnofsky performance status reflects the low inci-
dence of extensive chronic GVHD; the majority of the
patients had an excellent perf o rmance status. Patient age,
prior CMV infection, and female donor–male re c i p i e n t
pairs have been identified as potential risk factors for devel-
opment of chronic GVHD. When these variables were
c o m p a red between the two GVHD prophylaxis arms, no
differences were observed.
R e l a pse and sur v i v a l
Fifty-nine percent (88 of 150) of patients treated with
FTBI/VP-16 for acute leukemia in first remission or CML
in first chronic phase were alive with a minimum followup
>5 years. Overall survival did not differ between the two
GVHD prophylaxis groups. Overall survival (Fig. 1) was
66% (95% confidence interval [CI] 55–77) for the thre e -
drug regimen and 56% (95% CI 48–70%) for the two-drug
regimen (p = 0.28). Thirty-four patients who received the
two-drug regimen and 30 patients who received the three-
drug regimen relapsed or died. 
Relapse for patients with CML was defined as any clini-
cal, cytogenetic, or molecular  relapse. Patients who
responded to donor lymphocyte infusions were still
recorded as relapsed. Disease-free survival at 5 years (Fig. 2)
was 57% for patients receiving CSA/PSE and 62% for
patients receiving CSA/MTX/PSE (p = 0.42). When sur-
vival free of chronic GVHD was analyzed (Fig. 3), 42% of
patients receiving CSA/PSE and 52% of patients receiving
CSA/MTX/PSE were alive and free of chronic GVHD at
5 years (p = 0.29). Comparison of serum bilirubin and
degree of thrombocytopenia, known adverse prognostic fac-
tors for chronic GVHD [13], showed no diff e rence at the
time of diagnosis of chronic GVHD. Platelet count in the
CSA/MTX/PSE group was significantly lower on day 100
than in the CSA/PSE group (77,000 vs. 110,000; p < 0.02),
an observation that did not result in inferior overall or
chronic GVHD–free survival.
Causes of death
The leading causes of death in both arms were similar.
Infectious complications did not differ: seven patients in the
t w o - d rug and eight patients in the thre e - d rug arm died of
infections or interstitial pneumonitis. The overall incidence
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of relapse also did not differ, but seemed to favor the three-
drug arm (fewer relapses), a reassuring observation since the
incidence of acute GVHD was lower in that group. The
causes of death are presented in Table 2.
DISCUSSION
The incidence and severity of acute GVHD can be sub-
stantially reduced by the use of combination immunosup-
p ressive therapy. While steroids are first-line therapy for
treatment of acute and chronic GVHD, the effectiveness of
prednisone in preventing acute GVHD has been questioned
[14]. The overall incidence of clinically significant acute
GVHD was substantial in this series, and when compare d
with CSA and MTX, a similar number of patients experi-
enced grade II–IV acute GVHD despite the addition of
PSE. This series suggested that the use of pro p h y l a c t i c
steroids in combination with CSA was not beneficial in the
p revention of acute GVHD. In contrast to these re s u l t s ,
when prednisone was administered with CSA beginning on
Figure 1. Incidence of chronic GVHD
The majority of the patients had limited chronic GVHD.
Figure 2. Overall survival
Comparison of those receiving CSA/PSE vs. CSA/MTX/PSE.
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day 7 and compared with CSA alone, the incidence of grade
II–IV acute GVHD was significantly lower than that
observed with CSA alone [15]. Those results were noted in
patients with advanced hematologic malignancies and vary
substantially from the results re p o rted here. When pre d-
nisone given on a similar schedule and dosage (beginning on
day 7) was administered with CSA alone or CSA/MTX to
good-risk patients treated with a uniform conditioning regi-
men, the observed incidence of grade II–IV acute GVHD
was only 9–23%. These results with PSE in combination
with CSA, with or without MTX, are not inferior to those
re p o rted in similar good-prognosis leukemia patients
treated with CSA/MTX, in whom a 32% incidence of grade
II–IV acute GVHD has been observed [9].
The wide variance in incidence of acute GVHD in these
two studies of prophylactic PSE initiated on day 7 under-
s c o res the importance of evaluating GVHD pro p h y l a c t i c
regimens in homogeneous patient populations treated with
consistent conditioning regimens and supportive care
modalities.
In contrast to acute GVHD, the question of whether
c h ronic GVHD can be prevented has only rarely been
a d d ressed. T-cell depletion in genotype-matched sibling
transplantation decreases the incidence of chronic GVHD
but provides no survival advantage because of concomitant
increases in disease relapse and graft failure [16]. The com-
bination of cyclosporine and methotrexate, which is eff e c-
tive in limiting severity and incidence of acute GVHD, has
not significantly affected the rate of occurrence of chro n i c
GVHD. In a randomized comparative study of CSA/MTX
vs. CSA alone, which demonstrated a significant re d u c t i o n
of acute GVHD in favor of the combination drug regimen,
incidences of chronic GVHD were 46 and 58% in the two
treatment arms, respectively [9]. 
One might speculate about the lack of diff e rence in
c h ronic GVHD incidence, given that there was a statisti-
cally significant difference in the incidence of acute GVHD
in favor of the thre e - d rug arm. The pathophysiology of
c h ronic GVHD appears to be diff e rent from that of acute
GVHD and is likely caused by different cell populations (T
and non–T cells) or possibly diff e rent antigen-pre s e n t i n g
cells (donor vs. host). Recent data suggest that thymic and
extrathymic differentiation and expansion of T lymphocytes
are affected by acute GVHD [17,18]. The T-cell hypoplasia
that occurs in acute GVHD is primarily caused by changes
in the homeostasis of the peripheral immune compartment.
Resident dendritic cells are primary components of these
peripheral T-cell niches [19,20]. Damage to these secondary
sites of antigen presentation or to the thymus could lead to
p rolonged immunodeficiency and lack of development of
d o n o r-derived T-cell immunity. The simplest explanation
for the similar rates of chronic GVHD in spite of lower
incidence of acute GVHD is the small number of patients.
Also, the slow tapering off of prednisone and cyclosporine
Table 2. Leading causes of death
CSA/PSE/MTX CSA/PSE
n 75 74
Relapse 5 8
Acute GVHD 0 2
Chronic GVHD 6 8
Infection/interstitial pneumonitis 8 7
Organ failure 6 4
Veno-occlusive disease 0 2
Other 2* 3†
Total 27 34
*One patient died of anoxic brain damage and one of drug toxicity.
†One patient died of cardiac failure and one of suicide; one cause of death is
unknown.
Figure 3. Disease-free survival
Comparison of those receiving CSA/PSE vs. CSA/MTX/PSE.
290
may have an effect on subclinical chronic GVHD, resulting
in a lower incidence of extensive chronic GVHD. Moreover,
there may be many other competing events that may lead to
c h ronic GVHD besides just acute GVHD. This would be
similar to the observation that while the incidence of acute
GVHD was lower, there was not an impact on overall sur-
vival. Finally, the experience with thalidomide, which is use-
ful for the therapy of chronic GVHD and harmful when
used for prophylaxis of chronic GVHD, underscores the
tenuous balance of effector cell populations in the develop-
ment of chronic GVHD and our limited understanding of
the mediators of this process [21–23]. 
Use of prednisone in acute GVHD prophylaxis has been
suggested to lead to a higher incidence of chronic GVHD.
Since both patient groups received steroids, the pre s e n t
study does not allow us to address this issue. In this study,
no difference in incidence of chronic GVHD was observed
in patients receiving CSA/MTX/PSE compared with
CSA/PSE. With an overall incidence of chronic GVHD of
55%, and with limited chronic GVHD accounting for more
than half of the observed cases, these results do not diff e r
significantly from those reported with non–steroid-contain-
ing regimens. Specifically, as reported by Sullivan et al. [24],
43% of similarly aged patients undergoing marrow trans-
plantation from HLA-identical sibling donors developed
clinical extensive chronic GVHD. One possible explanation
is the observation that many patients still receive prednisone
in the form of treatment of acute GVHD after failing pri-
mary prophylaxis.
Chronic GVHD–free survival was not different between
the two prophylaxis programs. Timely resolution of chronic
GVHD would be expected to have important implications
for survivors of allogeneic transplantation. Prior studies
have suggested the importance of chronic GVHD in reduc-
ing leukemic relapse in certain subsets of patients and have
established chronic GVHD as an important determinant of
quality of life after transplantation [25]. At 5 years, 42–52%
of patients survive without immunosuppression and free of
chronic GVHD.
Overall survival between the two GVHD pro p h y l a x i s
regimens also did not differ. Moreover, with an overall fol-
low-up of 4.5 years, long-term survival and disease-free sur-
vival are comparable to those observed with non–stero i d -
containing GVHD prophylaxis regimens in similar
good-risk patient populations. Median survival for all
patients treated with FTBI and etoposide as a conditioning
regimen and either CSA/MTX/PSE or CSA/PSE has not
yet been reached and is ,9 years. Current data suggest that
the combination of CSA with sequential MTX and PSE as
acute GVHD prophylaxis results in decreased acute GVHD
and comparable chronic GVHD–free survival without
a p p a rent increased risk of leukemic relapse in patients
undergoing transplantation for acute leukemia in first remis-
sion or CML in first chronic phase. Based on these observa-
tions, further exploration of the importance of steroids in
the prophylaxis of GVHD prophylaxis is warranted. An
ongoing randomized trial at Stanford University Medical
C e n t e r, City of Hope National Medical Center, and Duke
University is comparing CSA/MTX/PSE vs. CSA/MTX as
prophylaxis against acute GVHD in candidates undergoing
sibling matched allogeneic transplantation. That trial will
continue to define the impact of PSE on acute GVHD,
chronic GVHD, disease-free survival, and leukemic relapse.
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